Furosemide (Frusemide) - Intravenous |
SCOPE (Area): Acute, Emergency, ICU, General Wards, Theatre, (Exclude: Paediatrics Seek Advice), Cardiovascular Suite, Coronory Care Unit, Grampians Health At Home (ballarat) |
SCOPE (Staff): Medical, Nursing, Pharmacy |
Printed versions of this document SHOULD NOT be considered up to date / current Exclusions
Paediatrics (seek Paediatrician advice). |
Preamble
See Appendix 1 for full version of this Drug Guideline. |
Related Documents
References
 |
Alfred Health (2020, March). Intravenous Frusemide (Furosemide) Drug Guideline. Alfred Health. Retrieved March 21, 2023 from https://app.prompt.org.au/search. |
 |
Barwon Health (2018, March). Furosemide (Frusemide) Intravenous Drug Protocol. Barwon Health. Personal communication received February 2019. |
 |
CRC Press Taylor and Francis Group. (2022). Renal Drug Database. Retrieved May 24, 2022. |
 |
Khan, D., Knowles, S., Shear, N. (2019) Sulfonamide Hypersensitivity: Fact and Fiction. The Journal of Allergy and Clinical Immunology: In Practice, 7 (7), 2116-2123. https://doi.org/10.1016/j.jaip.2019.05.034 |
 |
MIMS Online. (2022). MIMS Online, Lasix High Dose product information. Retrieved May 24, 2022. |
 |
Rossi, S. (2022). Australian Medicines Handbook. Retrieved May 24, 2022. |
 |
The Society of Hospital Pharmacists of Australia. (2022). Australian Injectable Drugs Handbook (8th ed.). Retrieved May 24, 2022. |
 |
Therapeutic Guidelines Limited. (2022). Therapeutic Guidelines. Retrieved May 24, 2022. |
 |
Walters Kluwer. (2019) Lexicomp, Furosemide Drug Information. Retrieved December 3rd, 2019. |
 |
Walters Kluwer. (2022) UpToDate, Drug Interaction section. Retrieved May 24, 2022. |
Appendix
Reg Authority: Medication Safety & Governance Committee (MSGC) |
Date Effective: 03/04/2023 |
Review Responsibility: Pharmacist - Rotational |
Date for Review: 30/09/2024 |
Furosemide (Frusemide) - Intravenous - DRG0009 - Version: 8 - (Generated On: 25-07-2025 05:52) |